TNFRSF8 positive
|
HL
|
TNFRSF8 positive
|
HL
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
penpulimab Sensitive: A1 - Approval
|
penpulimab Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
AB122 Sensitive: A1 - Approval
|
AB122 Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
R-CHOP Sensitive: A2 - Guideline
|
R-CHOP Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
R-CVP Sensitive: A2 - Guideline
|
R-CVP Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
bortezomib Sensitive: A2 - Guideline
|
bortezomib Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
everolimus Sensitive: A2 - Guideline
|
everolimus Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
carboplatin + etoposide oral + bendamustine Sensitive: A2 - Guideline
|
carboplatin + etoposide oral + bendamustine Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
bendamustine Sensitive: A2 - Guideline
|
bendamustine Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
nivolumab + brentuximab vedotin Sensitive: A2 - Guideline
|
nivolumab + brentuximab vedotin Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
GemOx Sensitive: A2 - Guideline
|
GemOx Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
ICE Sensitive: A2 - Guideline
|
ICE Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
ESHAP Sensitive: A2 - Guideline
|
ESHAP Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
DHAP Sensitive: A2 - Guideline
|
DHAP Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
R-ESHAP Sensitive: A2 - Guideline
|
R-ESHAP Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
MINE Sensitive: A2 - Guideline
|
MINE Sensitive: A2 - Guideline
|
No biomarker
|
HL
|
No biomarker
|
HL
|
BEACOPP Sensitive: A2 - Guideline
|
BEACOPP Sensitive: A2 - Guideline
|
TNFRSF8 positive
|
HL
|
TNFRSF8 positive
|
HL
|
AFM13 Sensitive: C2 – Inclusion Criteria
|
AFM13 Sensitive: C2 – Inclusion Criteria
|
CHD8 mutation
|
HL
|
CHD8 mutation
|
HL
|
sintilimab Resistant: C3 – Early Trials
|
sintilimab Resistant: C3 – Early Trials
|
CELF2 mutation
|
HL
|
CELF2 mutation
|
HL
|
sintilimab Resistant: C3 – Early Trials
|
sintilimab Resistant: C3 – Early Trials
|
ABCC2 underexpression
|
HL
|
ABCC2 underexpression
|
HL
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
PD-1 underexpression
|
HL
|
PD-1 underexpression
|
HL
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
CD163 overexpression
|
HL
|
CD163 overexpression
|
HL
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
CD14 overexpression
|
HL
|
CD14 overexpression
|
HL
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
TNFRSF8 positive
|
HL
|
TNFRSF8 positive
|
HL
|
TT11 Sensitive: C3 – Early Trials
|
TT11 Sensitive: C3 – Early Trials
|
TNFRSF14 mutation
|
HL
|
TNFRSF14 mutation
|
HL
|
sintilimab Resistant: C3 – Early Trials
|
sintilimab Resistant: C3 – Early Trials
|
MHC-II expression
|
HL
|
MHC-II expression
|
HL
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
CASP3 underexpression + BCL2 positive
|
HL
|
CASP3 underexpression + BCL2 positive
|
HL
|
ABVD Resistant: C3 – Early Trials
|
ABVD Resistant: C3 – Early Trials
|
CASP3 overexpression
|
HL
|
CASP3 overexpression
|
HL
|
ABVD Sensitive: C3 – Early Trials
|
ABVD Sensitive: C3 – Early Trials
|
BCL2 expression
|
HL
|
BCL2 expression
|
HL
|
ABVD Resistant: C3 – Early Trials
|
ABVD Resistant: C3 – Early Trials
|
CASP3 overexpression + BCL2 negative
|
HL
|
CASP3 overexpression + BCL2 negative
|
HL
|
ABVD Sensitive: C3 – Early Trials
|
ABVD Sensitive: C3 – Early Trials
|
B2M mutation
|
HL
|
B2M mutation
|
HL
|
sintilimab Resistant: C3 – Early Trials
|
sintilimab Resistant: C3 – Early Trials
|
TNFRSF8 overexpression
|
HL
|
TNFRSF8 overexpression
|
HL
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
Chr amplification(9)(p24.1)
|
HL
|
Chr amplification(9)(p24.1)
|
HL
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
BCL2 overexpression
|
HL
|
BCL2 overexpression
|
HL
|
venetoclax Resistant: D – Preclinical
|
venetoclax Resistant: D – Preclinical
|
CD123 positive
|
HL
|
CD123 positive
|
HL
|
VIP943 Sensitive: D – Preclinical
|
VIP943 Sensitive: D – Preclinical
|
BCL2 expression
|
HL
|
BCL2 expression
|
HL
|
venetoclax Sensitive: D – Preclinical
|
venetoclax Sensitive: D – Preclinical
|
XPO1 E571K
|
HL
|
XPO1 E571K
|
HL
|
venetoclax + selinexor Sensitive: D – Preclinical
|
venetoclax + selinexor Sensitive: D – Preclinical
|
XPO1 E571K
|
HL
|
XPO1 E571K
|
HL
|
venetoclax Sensitive: D – Preclinical
|
venetoclax Sensitive: D – Preclinical
|